金沙(8888js-官方JS认证)-Made in China

Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase 3 clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase 3 clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. 

It is the first dual mAbs combination therapy to receive IND approval from the NMPA for the treatment of advanced solid tumours. Subject enrollment has been completed in a Phase 2 clinical trial for the treatment of advanced HCC. First patients have been dosed in a Phase 3 clinical trial for the treatment of nsNSCLC and a Phase 2/3 clinical trial for mCRC in China.

The Company's second dual mAbs combination therapy. It is for the treatment of SCCHN. The first patient was dosed in China in a Phase 2 clinical trial for the treatment of recurrent or metastatic SCCHN.

The Phase 2 IND application of serplulimab in combination with HLX07 for the treatment of solid tumours was granted by the NMPA.

The first subject dosed of a Phase 2 study of serplulimab combined with HLX07 in first-line EGFR high expression sqNSCLC patients.

HANSIZHUANG (serplulimab) in combination with HANBEITAI (bevacizumab biosimilar) and HLX07 (innovative anti-EGFR mAb)  for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) has been approved by the National Medical Products Administration (NMPA).

First subject doesd for phase 1 clinical trial  of HANSIZHUANG (serplulimab) in combination with HLX26, an innovative anti-LAG-3 mAb, for the treatment of advanced/metastatic solid tumours. 

HLX11, recombinant anti-HER2 domain II humanised monoclonal antibody injection, a pertuzumab biosimilar. 

It can be used in combination with trastuzumab and chemotherapy for adjuvant treatment and neoadjuvant treatment for patients with HER2-positive BC and HER2-positive mBC. The first subject has been dosed in multi-centre phase 3 clinical trial of HLX11 for the neoadjuvant therapy in patients with HER2-positive, HR-negative early or locally advanced breast cancer. 

HLX22,  humanised IgG1 monoclonal antibody injection targeting human epidermal growth factor receptor-2 (HER2). 

First patient has been dosed in Phase 2 clinical trial to compare HLX22 in combination with 汉曲优® (trastuzumab) and chemotherapy as first-line therapy for HER2-positive locally advanced or metastatic gastric cancer patients in Chinese mainland.

HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. 

It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase 1 clinical study (HLX07FIH, NCT02648490) for the treatment of advanced solid tumours. Tumour response was observed in this study and preliminary efficacy of HLX07 was established.

HLX26, a recombinant anti-LAG-3 human monoclonal antibody injection, is an innovative monoclonal antibody independently researched and developed by Henlius. LAG-3 is an immune checkpoint receptor and is regarded as a new generation of immunotherapy target after PD-1/L1 and CTLA-4. 

The first subject has been dosed with HLX26 for the Phase 1 clinical trial in patients with advanced/metastatic solid tumours or lymphomas.

HLX6018 is a novel anti-GARP/TGF-β1 monoclonal antibody (mAb). Its IND application has been approved by the National Medical Products Administration (NMPA) for the treatment of idiopathic pulmonary fibrosis (IPF). HLX6018 is the first innovative product of Henlius in the treatment field of chronic inflammatory diseases. As of now, no mAb targeting GARP/TGF-β1 has been approved for marketing globally.

HLX43 is a novel PD-L1-targeting ADC, comprised of a high-affinity humanized IgG1 mAb targeting PD-L1 conjugated with a novel cytotoxic payload through cleavable linkers, with the drug-to-antibody ratio is about 8. As of now, the IND applications of HLX43 has been approved by the by the China NMPA and U.S. FDA, for the treatment of advance/metastatic solid tumours. Meanwhile, the first subject was dosed for a phase 1 clinical trial of HLX43 in China. 

HLX42 is a novel EGFR-targeting ADC, comprised of a high-affinity humanized IgG1 mAb targeting EGFR conjugated with a novel cytotoxic payload through cleavable linkers, with the drug-to-antibody ratio is about 8. As of now, the IND applications of HLX42 has been approved by the by the China NMPA and U.S. FDA, for the treatment of advance/metastatic solid tumours.

HLX51 is a novel humanised agonistic anti-OX40 monoclonal antibody (mAb). Its IND application has been approved by the National Medical Products Administration (NMPA) for the treatment of patients with advanced/metastatic solid tumours and lymphomas. At present, there is no anti-OX40 mAb has been approved for marketing globally.

HLX17, recombinant anti-PD-1 humanized monoclonal antibody injection, a pembrolizumab biosimilar. It is to be potentially used for the treatment of indications that reference pembrolizumab has been approved, including melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell cancer, colorectal cancer, hepatocellular carcinoma, biliary tract cancer, triple-negative breast cancer, microsatellite instability-high or mismatch repair deficient cancer, and gastric cancer, etc. Its IND application was approved by the National Medical Products Administration (NMPA) .